OpenArc Corporate Advisory, LLC
Position in ARQT — Arcutis Biotherapeutics, Inc.
CIK 2111345
ATLANTA, GA
Position in ARQT
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$720,771
-$167,882 QoQ
Shares Held
30,593
-0.0% QoQ
Ownership
0.024%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ARQT Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026OpenArc Corporate Advisory, LLC holds $9,069,428 across 15 Biotechnology names. ARQT ranks #5 (7.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GLUE |
Monte Rosa Therapeutics, Inc.
|
100,227 | $1,648,734 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
19,987 | $1,291,759 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,395 | $1,069,463 | |
| 4 | TVTX |
Travere Therapeutics, Inc.
|
31,000 | $921,010 | |
| 5 | ARQT |
Arcutis Biotherapeutics, Inc.
This page
|
30,593 | $720,771 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
809 | $625,065 | |
| 7 | PBYI |
Puma Biotechnology, Inc.
|
89,491 | $571,847 | |
| 8 | ALLO |
Allogene Therapeutics, Inc.
|
172,258 | $420,309 |
All Filings in ARQT
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $720,771 | 30,593 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $888,653 | 30,601 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||